Baidu
map

两部门部署中医药教育改革:创新人才培养模式

2017-08-05 佚名 中国新闻网

据教育部网站消息,教育部与国家中医药管理局日前联合发布《关于医教协同深化中医药教育改革与发展的指导意见》,从多方面对中医药教育改革与发展做出部署,要求创新中医药人才培养模式,提高中医药人才培养质量;逐步建立中医药师承教育制度,提高中医药传承创新能力。

据教育部网站消息,教育部与国家中医药管理局日前联合发布《关于医教协同深化中医药教育改革与发展的指导意见》,从多方面对中医药教育改革与发展做出部署,要求创新中医药人才培养模式,提高中医药人才培养质量;逐步建立中医药师承教育制度,提高中医药传承创新能力。

《指导意见》指出中医药教育改革的总体目标与重点任务是:到2020年,基本建成院校教育、毕业后教育、继续教育三阶段有机衔接,师承教育贯穿始终,符合中医药事业发展要求和学科特色的中医药人才培养体系。院校教育质量得到显着提高,毕业后教育得到有效普及,继续教育实现全面覆盖,师承教育优势得到充分发挥。

围绕中医药医疗、保健、教育、科研、产业、文化和对外交流与合作全面协调发展需求,着力推进以“5+3”(5年中医学本科教育+3年中医住院医师规范化培训或3年中医硕士专业学位研究生教育)为主体、以“3+2”(3年中医学专科教育+2年中医类别助理全科医生培训)为补充的中医临床人才培养,加快推进中医药健康服务技术技能人才培养,统筹推进多类型中医药人才培养,建立和完善符合中医药行业特点、以职业胜任能力和创新创业能力提升为主线的人才培养、评价、激励机制,形成有利于优秀中医药人才脱颖而出的政策环境和社会氛围。

《指导意见》提出多方面主要举措:

一是,深化院校教育改革,提高中医药人才培养质量。

《指导意见》指出,要创新中医药人才培养模式。落实立德树人的根本任务,强化德育为先、能力为重、通专融合的教育理念,坚持继承与创新相结合、理论与实践相结合、共性培养与个性发展相结合,着力加强中医药思维培养与实践能力、传承创新能力和人文精神的同步提升。

优化中医药学科专业结构。围绕建设“世界一流大学和一流学科”的总体要求,加强中医药重点学科建设,打造一批世界一流的中医药名校和学科。

改革中医药课程体系。推进中医药课程内容整合与优化,构建以中医药传统文化与经典课程为根基,以提升中医药健康服务能力为导向的课程体系。加强基础与临床课程的贯通,实现理论与实践的充分融合。

加强中医药实践教学能力建设。进一步理顺中医药院校与其附属医院、教学医院的关系,明确并强化附属医院、教学医院临床教学主体职能,充分发挥中医药院校附属医院在中医药临床教学、住院医师规范化培训中的示范引领作用。

强化中医药师资队伍建设。建设若干国家中医药教师发展中心,实施高水平“双师型”师资和优秀教学团队发展计划,加强师承导师、学科带头人、中青年骨干教师培养。

健全中医药教育质量保障体系。推进建立涵盖院校教育和毕业后教育的质量保障机制,充分发挥国家高等中医药教育质量监测中心作用。加快建立中医药专业认证制度。积极推进中医类别执业医师分阶段考试改革。

加强中医药教育对外交流与合作。加快建立中医药教育国际标准体系,加大与国际组织、外国政府和地区以及高等学校之间的中医药国际教育交流与合作,鼓励中医药院校在境外开办中医孔子学院、中医药中心。

二是,要建立健全毕业后教育制度,培养合格中医临床医师。

全面实施中医住院医师规范化培训。完善中医住院医师规范化培训相关政策机制,统筹兼顾中医类专业学生数量和培训基地培养能力,合理确定培训规模。

探索开展中医医师专科规范化培训。在全面提高中医医师临床诊疗能力基础上,科学设定培训专科,开展中医医师专科规范化培训试点。

积极推进中医类别全科医生(助理全科医生)培养。健全中医全科专业培训体系,鼓励中医药院校设立全科医学系,将中医全科作为中医住院医师规范化培训的急需紧缺专业进行重点招收培训。加大支持力度,提升中医全科岗位吸引力。

三是,完善继续教育体系,提升中医药人才队伍整体素质。

扩大中医药继续教育覆盖面。以满足中医药人员职业发展需求为导向,以岗位胜任能力为核心,以突出中医药特色优势为重点,广泛深入开展各种适宜有效的中医药继续教育活动,不断提升中医药人员的职业素质能力。

创新中医药继续教育模式。加强统筹管理,充分利用中医药院校、中医医疗机构等的教学资源,发挥中医药行业学术团体的优势和作用,创新中医药继续教育模式及管理方法,探索开展“互联网+”中医药继续教育,提高中医药继续教育的针对性、有效性和便捷性。

健全中医药继续教育体系。加强中医药继续教育政策制度、组织管理、师资队伍、信息化建设和日常监管,鼓励优秀中医药人才承担继续教育教学工作。

四是,加强师承教育,提高中医药传承创新能力。

逐步建立中医药师承教育制度。将师承教育贯穿于中医药人才培养全过程,发挥师承教育独特作用,总结师承教育规律,制定师承教育标准和相关政策措施,建立师承教育运行机制,完善师承教育考评和监管体系,推动师承教育全面发展。

创新师承教育与院校教育、毕业后教育相结合的人才培养模式。鼓励有条件的中医药院校将师承教育全面覆盖中医药类专业学生,推动中医药研究生教育与师承教育的有机衔接,提高院校教育教学质量。

推进师承教育模式的人才培养专项建设。深入开展全国老中医药专家学术经验继承工作、名老中医药专家和中医学术流派传承工作室建设、中药特色技术传承人才培养等不同层次、不同类型的师承教育项目。

《指导意见》并提出多项保障措施,主要包括:建立推进中医药教育改革与发展的政策保障机制。健全国家、省级教育行政部门和中医药管理部门之间的中医药教育工作协调机制,加强对中医药人才培养的宏观规划、政策保障、工作指导和质量监控,在专业设置、教学管理、模式创新、评价考核等方面给予高等学校更多自主权。

建立中医药教育投入保障机制。各级教育、中医药行政管理部门要积极协调发展改革、财政等部门,根据中医药人才培养的特点,进一步加大中医药教育财政补助。

建立完善中医药人才评价与激励机制。积极推动完善中医药专业技术职务评审考核机制,注重实践能力、工作绩效、职业素养的考评。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2018-07-15 日月
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-07 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-06 184****9840

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 1ddf0692m34(暂无匿称)

    学习了,很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1675423, encodeId=1b0916e54231c, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Sun Jul 15 09:04:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285395, encodeId=f6fc12853958c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409018, encodeId=c2c5140901896, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554870, encodeId=d74915548e093, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Mon Aug 07 09:04:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230563, encodeId=d0cb23056342, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 06 07:09:03 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230449, encodeId=9d7b23044979, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Aug 05 21:45:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230425, encodeId=96dd230425b6, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Aug 05 19:45:27 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 131****1460

    学习了受益匪浅。

    0

相关资讯

张伯礼院士:青蒿素的研究与发展

以中国中医科学院中药研究所屠呦呦研究员为代表的科研人员在青蒿素抗疟研究方面取得了丰硕的成果。1977 年3 月,《科学通报》发表了以“青蒿素结构研究协作组”的名义撰写的《一种新型的倍半萜内酯——青蒿素》的论文, 首次公开了青蒿素结构研究信息。文章的发表受到了政府和国家有关部门的高度重视, 促进了青蒿素的开发和研究。2015 年, 屠呦呦研究员因发现青蒿素而获得诺贝尔生理学或医学奖。近40 年来,

王凤云:探寻并推广中医药疗效的共性

中国医学科学院西苑医院脾胃科副主任王凤云主任医师本人比照片看起来更年轻,笑语盈盈的她,是个被岁月温柔相待的人。“原本大学时并不喜欢的中医专业,一路走来,却让我受益良多。”王凤云说,身心皆从中医处获益良多的她,此刻更愿意分享和为中医传承做点事。

江西发布中医药发展规划

近日,江西省政府办公厅印发《江西省“十三五”中医药发展规划》

重复:J Am Coll Cardiol:传统中医药治疗心血管疾病:证据和潜在的机制

2017年6月,发表在《J Am Coll Cardiol》的一项由中国科学家进行的系统综述,考察了传统中医药(TCM)治疗心血管疾病的证据和潜在的机制。

中国工程院院士张伯礼:使用中药可减少抗生素用量

“当前全球都在倡导减少抗生素的滥用,日前中国中医科学院的中医药替代抗生素系统研究已经取得了首批成果。”中国工程院院士、中医科学院院长张伯礼19日在重庆举行的“医药院士重庆行”战略咨询会上表示,中医药现代化发展需要施行大品种战略,加大创新药的深加工、深开发力度。

国务院发文:鼓励西医离职学中医

文件中明确表示,要“建立完善西医学习中医制度”。

Baidu
map
Baidu
map
Baidu
map